Omnicef and Pregnancy
Animal studies on Omnicef and pregnancy show no negative effects on the fetus, but the drug has not been studied in pregnant humans. Therefore, the FDA has classified Omnicef as a Category B medicine. If you are taking Omnicef and pregnancy occurs, your healthcare provider will weigh the benefits to you against any possible risks to your unborn child before making a recommendation.
Omnicef® (cefdinir) is considered a pregnancy Category B medicine by the U.S. Food and Drug Administration (FDA), which means that it has not been studied in pregnant women. However, when studied in pregnant animals, Omnicef showed no negative effects on the fetus.
The FDA uses a category system to classify the possible risks to a fetus when a specific medicine is taken during pregnancy. Pregnancy Category B is given to medicines that do not cause side effects to the fetus in animal studies but no human studies in pregnant women have been conducted.
However, it is important to note that animals do not always respond to medicines the same way that humans do. Therefore, a pregnancy Category B medicine may be given to a pregnant woman if the healthcare provider believes that the benefits to the mother outweigh any possible risks to the unborn child.
If you are taking Omnicef and pregnancy occurs, let your healthcare provider know. He or she will consider the benefits and risks of Omnicef during pregnancy before making a recommendation for your particular situation.